Gang Liu1,2, Xiaoyan Fan3, Ying Cai4, Zexian Fu1, Fei Gao1, Jiantao Dong1,2, Kang Li1, Jianhui Cai1,2,3. 1. Department of Surgery, Hebei Medical University, 361 East Zhongshan Road, Shijiazhuang 050017, China. 2. Department of Surgery, Hebei General Hospital, 348 Heping West Road, Shijiazhuang 050051, China. 3. Department of Oncology, Hebei General Hospital, 348 Heping West Road, Shijiazhuang 050051, China. 4. Department of Research and Development, Hebei Engineering Technology Research Center for Cell Therapy, Hebei HOFOY Biotech Corporation Ltd, 238 Changjiang Aveneu, Shijiazhuang 500350, China.
Abstract
AIM: To produce dendritic cells (DCs) from CD34+ stem cells from cord blood and explore their prophylactic and curative effect against tumors by vaccinating humanized NSG mice. MATERIALS & METHODS: Separated CD34+ stem cells from cord blood were cultured for 30 days, and the resultant DCs (CD34-DCs) were collected. The basic function of the CD34-DCs and the cytotoxicity of CD34-cytotoxic-T lymphocytes (CTLs) were tested in vitro, and tumor inhibition in a humanized NSG mouse tumor model was observed. RESULTS: The number of CD34-DCs reached approximately 9 log. These cells performed functions similar to those of DCs derived from monocytes from peripheral blood (PBMC-DCs). The CTLs of the CD34-DCs (CD34-CTLs) presented a better antitumor effect in vitro. The obvious prophylactic and therapeutic antitumor effects of the CD34-DC vaccine were observed in the humanized NSG mouse models. CONCLUSION: CD34-DCs from cord blood were sufficient in quantity and quality as a vaccine agent against tumors in vitro and in vivo.
AIM: To produce dendritic cells (DCs) from CD34+ stem cells from cord blood and explore their prophylactic and curative effect against tumors by vaccinating humanized NSG mice. MATERIALS & METHODS: Separated CD34+ stem cells from cord blood were cultured for 30 days, and the resultant DCs (CD34-DCs) were collected. The basic function of the CD34-DCs and the cytotoxicity of CD34-cytotoxic-T lymphocytes (CTLs) were tested in vitro, and tumor inhibition in a humanized NSG mousetumor model was observed. RESULTS: The number of CD34-DCs reached approximately 9 log. These cells performed functions similar to those of DCs derived from monocytes from peripheral blood (PBMC-DCs). The CTLs of the CD34-DCs (CD34-CTLs) presented a better antitumor effect in vitro. The obvious prophylactic and therapeutic antitumor effects of the CD34-DC vaccine were observed in the humanized NSG mouse models. CONCLUSION:CD34-DCs from cord blood were sufficient in quantity and quality as a vaccine agent against tumors in vitro and in vivo.
Authors: Ashwin Ajith; Vera Portik-Dobos; Daniel D Horuzsko; Rajan Kapoor; Laura L Mulloy; Anatolij Horuzsko Journal: Hum Immunol Date: 2020-02-21 Impact factor: 2.850
Authors: Giuseppe Lia; Clara Di Vito; Marco Cerrano; Lucia Brunello; Francesca Calcaterra; Marta Tapparo; Luisa Giaccone; Domenico Mavilio; Benedetto Bruno Journal: Front Immunol Date: 2020-03-20 Impact factor: 7.561